Evidence map›Paper›PMID 42277475›Full record

ArticleAnnals of surgical oncology2026

Predicting Failure of Active Surveillance in Desmoid-Type Fibromatosis Using Radiomics: An International Multi-center Cohort Study.

Stefanie N Hakkesteegt, Douwe J Spaanderman, Chiara Colombo, Anne-Rose W Schut, Andrea Vanzulli, Francesco Barretta, C Morosi, Marco Fiore, Peter Ferguson, Harini Suraweera and 15 more

Abstract readMulticenter Study
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Stefanie N HakkesteegtDepartment of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Douwe J SpaandermanDepartment of Radiology and Nuclear Medicine, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Chiara ColomboDepartment of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Anne-Rose W SchutDepartment of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Andrea VanzulliDepartment of Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Francesco BarrettaDepartment of Biostatistics for Clinical Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
C MorosiDepartment of Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Marco FioreDepartment of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Peter FergusonDivision of Orthopaedic Surgery, Department of Surgery, Sinai Health System, University of Toronto Musculoskeletal Oncology Unit, Toronto, Canada.
Harini SuraweeraDepartment of Surgical Oncology, Department of Surgery, University of Toronto, Toronto, ON, Canada.
Anthony M GriffinDivision of Orthopaedic Surgery, Department of Surgery, Sinai Health System, University of Toronto Musculoskeletal Oncology Unit, Toronto, Canada.
Lawrence M WhiteToronto Joint Department of Medical Imaging, Sinai Health System, Women's College Hospital,, University Health Network, Toronto, ON, Canada.
Joel ShapiroDepartment of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Danchen GeDepartment of Radiology and Nuclear Medicine, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Dirk J GrünhagenDepartment of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Geert J L H van LeendersDepartment of Pathology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
David HanffDepartment of Radiology and Nuclear Medicine, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Jacob J VisserDepartment of Radiology and Nuclear Medicine, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Wiro J NiessenDepartment of Radiology and Nuclear Medicine, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Stefan KleinDepartment of Radiology and Nuclear Medicine, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Dutch Grafiti Research Group
Rebecca A GladdyDepartment of Surgical Oncology, Department of Surgery, University of Toronto, Toronto, ON, Canada.
Alessandro GronchiDepartment of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Cornelis VerhoefDepartment of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Martijn P A StarmansDepartment of Radiology and Nuclear Medicine, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands. m.starmans@erasmusmc.nl.

Funding

Nederlandse Organisatie voor Wetenschappelijk Onderzoek NGF.1607.22.025
6 · The paper itself

Abstract

backgroundActive surveillance (AS) is the first-line approach for desmoid-type fibromatosis (DTF). However, 30 % of patients require active treatment. Identifying these patients will help upfront to define a personalized treatment approach. This study assessed whether radiomics can predict AS failure in patients with DTF.

methodsThis multicenter study included data from the Netherlands (NL), Italy (ITA), and Canada (CAN). The study included patients with extra-abdominal DTF initially managed with AS and baseline MRI. Tumors were segmented using a minimally interactive deep-learning method, and radiomics features were extracted from T1-weighted (T1W) and T2-weighted (T2W) MRI scans. Prediction models to predict AS failure versus no failure were created using various machine-learning approaches. Both an internal cross-validation using all available data and an external leave-one-country-out cross-validation were used to assess model performance.

resultsThe cohort included 200 patients (72 NL, 62 ITA, 66 CAN), with AS failing for 26 % of the patients. Internal validation of the T1W+T2W imaging model resulted in an overall area under the curve (AUC) of 0.69 (95 % confidence interval [CI] 0.60-0.79). External validation resulted in an AUC of 0.58 (95 % CI 0.42-0.74) in the Dutch cohort, 0.76 (95 % CI 0.60-0.91) in the Italian cohort, and 0.77 (95 % CI 0.65-0.89) in the Canadian cohort. Adding clinical features did not improve the models' performance.

conclusionsPredicting AS failure with radiomics showed reasonable performance and generalized well to the Italian and Canadian cohorts. Pending improvements to the model or patient selection, the authors' model shows potential to better identify which DTF patients will benefit from AS and which will not.

Indexed as

Desmoid TumorsMagnetic Resonance ImagingRadiomicsAdolescentAdultCanadaFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisYoung Adult

Identifiers

PMID42277475
PMCPMC13452830

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.